Short Reads


Roche announced a $5.7 billion hostile takeover bid for Illumina. Under the terms of the proposed deal, Roche would acquire all outstanding Illumina shares for $44.50 each. Roche also announced its picks for Illumina's board of directors, should the deal go through. In response, Illumina's board of directors adopted a poison pill provision.

In a separate announcement, Illumina's board unanimously rejected Roche's offer, calling
it "grossly inadequate."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.